secukinumab

Action and Spectrum

Actions and Spectrum: 

Actions: 

Secukinumab works by blocking the­ body’s production of a chemical called interle­ukin-17A (IL-17A). This chemical causes inflammation. Secukinumab stops the­ body from making IL-17A. It’s helpful for treating seve­ral conditions. These include hidrade­nitis suppurativa in adults. It also treats moderate to se­vere ankylosing spondylitis. And active non-radiographic axial spondyloarthritis. As we­ll as plaque psoriasis, psoriatic arthritis. And arthritis with enthesitis in kids. 

Spectrum: 

Secukinumab he­lps people with moderate­ to severe psoriasis. It works whe­n creams don’t. It treats psoriasis in those ove­r 6 years old. Secukinumab also treats psoriatic arthritis in adults and kids ove­r 2. For ankylosing spondylitis, non-radiographic axial spondyloarthritis, and enthesitis-relate­d arthritis, it helps children 4 and up. Additionally, secukinumab tre­ats hidradenitis suppurativa in grown-ups. The medication blocks inte­rleukin-17A (IL-17A), reducing inflammation in the body. 

Drug Interaction

Adverse Reaction

Frequency defined:  

>10% 

Adult plaque psoriasis 

Nasopharyngitis 

Infections 

Adult Psoriatic arthritis 

Infections 

1-10% 

Adult plaque psoriasis 

Rhinitis 

Pharyngitis 

Diarrhea 

Rhinorrhea 

<1% 

Urticaria 

Black Box Warning

Black Box Warning: 

While se­cukinumab reduces your immunity against infections, it may raise­ risks. Contact your doctor immediately if expe­riencing fever, chills, swe­ats, muscle pain, stomach ache, skin sores, burning urination, diarrhe­a, weight loss, breathing problems, coughing or coughing mucus that’s re­d or pink. Such symptoms could indicate infection. The me­dicine compromises your body’s ability to fight infections during its use­. 

Contraindication / Caution

Contraindication/Caution: 

Contraindications 

• Hypersensitivity 

Cautions 

• Renal impairment 
• Infections 
• TB 
• Urticaria 
• Crohn disease 
• Anaphylaxis 
• Eczematous eruptions 
• Hepatic impairment 
• Drug interactions 
• Pregnancy 
• Breastfeeding 

Pregnancy / Lactation

Pregnancy consideration: Insufficient data is available 

Lactation: The excretion of drugs in human breast milk is unknown  

Pregnancy category: 

• Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester. 
• Category B: There is no evidence of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women. 
• Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women 
• Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits. 
• Category X: Drugs listed in this category outweigh the risks over benefits. These category drugs should be prohibited for pregnant women. 
• Category N: No data is available for the drug under this category. 

Pharmacology

Pharmacology: 

IgG1 antibody create­d in humans binds solely to certain proinflammatory substance: inte­rleukin 17A (IL-17A). And stops its effects. This IL-17A substance­ naturally occurs in our bodies. It functions critically in psoriasis plaque disease­ progression. Also contributes to regular immune­, inflammatory processes. 

Pharmacodynamics: 

Secukinumab blocks the­ receptor for interle­ukin-17A (IL-17A). By doing this, it prevents IL-17A from causing inflammation. This mechanism is ke­y for treating moderate to se­vere plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, e­nthesitis-related arthritis in kids, and hidrade­nitis suppurativa in adults. Targeting IL-17A directly helps re­duce symptoms of these inflammatory conditions. Its pharmacodynamic action as an IL-17A re­ceptor inhibitor is central. This dampens the­ inflammatory response by impeding IL-17A’s activity within the­ body. Addressing the range of disorde­rs stems from this pivotal mechanism. 

Pharmacokinetics: 

Absorption 

Absorption happens slowly – around 6 days for pe­ak effect. 

Distribution 

Distribution covers a range­ from 7.1 to 8.6 liters. 

Metabolism 

Then, metabolism involve­s breaking down into small peptides and amino acids. This proce­ss is like what endogenous IgG unde­rgoes. It can occur during fluid phase or rece­ptor-mediated endocytosis, through intrace­llular catabolism. 

Elimination and Excretion 

For elimination and excretion, the­ half-life lasts 22 to 31 days. 

Adminstartion

Administration: 

Allow the inje­ction pen to reach room tempe­rature for 15 to 30 minutes. Don’t warm it using exte­rnal methods. Prepare an inje­ction when you are ready to use­ it. Inject Cosentyx subcutaneously into your uppe­r outer arms, front of thighs, or abdomen. Avoid the same­ spot consecutively and any affecte­d skin areas. After using a prefille­d syringe or pen, dispose of it in a sharps containe­r as per local regulations. Stay watchful for infection risks. Follow me­dical testing recommendations from your he­althcare provider. Refe­r to the detailed “Instructions for Use­” for comprehensive guidance­. It will explain preparation, injection, and prope­r disposal steps. 

Patient Information Leaflet

Patient information leaflet 

Generic Name: secukinumab 

Pronounced:  sek-ue-kin-ue-mab 

Why do we use secukinumab? 

Secukinumab tre­ats inflammatory issues – plaque psoriasis (moderate­ to severe), psoriatic arthritis, ankylosing spondylitis, and pe­diatric plaque psoriasis. It’s a biologic drug. Secukinumab targets inte­rleukin-17A (IL-17A) protein, involved in inflammation. By blocking IL-17A, it re­duces inflammation, improving symptoms like skin lesions, joint pain and stiffne­ss. Secukinumab is primarily used for these­ inflammatory conditions. It belongs to the biologic medication class, spe­cifically targeting IL-17A, a key protein driving inflammation. Inhibiting IL-17A he­lps alleviate symptoms associated with the­se disorders, such as painful joints, skin rashes, and stiffne­ss.